Xolair (Omalizumab)

omalizumab 300 mg/2 mL injection, 2 mL pen device · INJECTION · PBS code 14930T

AUTHORITY_REQUIRED

What it costs

AU$418.14 PBS-determined price per 1 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2025-08-01.
• Repeats: 5.
• PBS program: HS.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Severe chronic spontaneous urticaria

Continuing treatment

Must be treated by a clinical immunologist; or

Must be treated by an allergist; or

Must be treated by a dermatologist; or

Must be treated by a general physician with expertise in the management of chronic spontaneous urticaria (CSU); AND

Patient must have demonstrated a response to the most recent PBS-subsidised treatment with this drug for this condition; AND

Patient must not receive more than 24 weeks per authorised course of treatment under this restriction.

Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.